E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma.

Autor:	Tarhini AA; Cleveland Clinic and Case Comprehensive Cancer Center, Cleveland, Ohio. tarhina1@ccf.org.; University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Lee SJ; ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Li X; Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Boston, Massachusetts., Rao UNM; University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Nagarajan A; Cleveland Clinic Florida, Weston, Florida., Albertini MR; University of Wisconsin Carbone Cancer Center, Madison, Wisconsin., Mitchell JW Jr; Mt. Carmel Health System, Columbus, Ohio., Wong SJ; Medical College of Wisconsin, Milwaukee, Wisconsin., Taylor MA; Lewis Cancer and Research Pavilion at St. Joseph's, Savannah, Georgia., Laudi N; Minnesota Oncology Hematology PA, Minneapolis, Minnesota., Truong PV; University of Kansas-Wichita, Wichita, Kansas., Conry RM; University of Alabama at Birmingham, Birmingham, Alabama., Kirkwood JM; University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Jazyk:	angličtina
Zdroj:	Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 Jan 15; Vol. 25 (2), pp. 524-532. Date of Electronic Publication: 2018 Nov 12.
DOI:	10.1158/1078-0432.CCR-18-2258
Abstrakt:	Purpose: Interferon-α favors a Th1 shift in immunity, and combining with ipilimumab (ipi) at 3 or 10 mg/kg may downregulate CTLA4-mediated suppressive effects, leading to more durable antitumor immune responses. A study of tremelimumab and high-dose interferon-α (HDI) showed promising efficacy, supporting this hypothesis. Patients and Methods: E3611 followed a 2-by-2 factorial design (A: ipi10+HDI; B: ipi10; C: ipi3+HDI; D: ipi3) to evaluate (i) no HDI versus HDI (across ipilimumab doses) and (ii) ipi3 versus ipi10 (across HDI status). We hypothesized that median progression-free survival (PFS) would improve from 3 to 6 months with HDI versus no HDI and with ipi10 versus ipi3. Results: For eligible and treated patients ( N = 81) at a median follow-up time of 29.8 months, median PFS was 4.4 months [95% confidence interval (CI), 2.7-8.2] when ipilimumab was used alone and 7.5 months (95% CI, 5.1-11.0) when HDI was added. Median PFS was 3.8 months (95% CI, 2.6-7.5) with 3 mg/kg ipilimumab and 6.5 months (95% CI, 5.1-13.5) with 10 mg/kg. By study arm, median PFS was 8.0 months (95% CI, 2.8-20.2) in arm A, 6.2 months (95% CI, 2.7-25.7) in B, 5.7 months (95% CI, 1.5-11.1) in C, and 2.8 months (95% CI, 2.6-5.7) in D. The differences in PFS and overall survival (OS) did not reach statistical significance. Adverse events were consistent with the known profiles of ipilimumab and HDI and significantly higher with HDI and ipi10. Conclusions: Although PFS was increased, the differences resulting from adding interferon-α or a higher dose of ipilimumab did not reach statistical significance and do not outweigh the added toxicity risks. (©2018 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu